About Scienture

Developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., brand-name Arbli (losartan potassium) oral suspension is recommended for the treatment of hypertension in patients greater than 6 years old.¹

Losartan is also indicated for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes.¹

Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients, physicians, and caregivers by offering novel specialty products to satisfy unmet patient needs. The assets in development at Scienture span across therapeutic areas and indications and are intended to cater to different market segments and channels.

Learn More About Scienture LLC

Scienture Holdings, Inc. (NASDAQ: SCNX) is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians, and caregivers by offering novel specialty products to satisfy unmet patient needs.

View Scienture’s Product Pipeline

Research shows difficulty swallowing pills directly impacts medication adherence, which can lead to serious health consequences:⁴

• Physical discomfort when attempting to swallow pills
• Anxiety and fear around medication times
• Incomplete medication ingestion or tablet regurgitation
• Improper modification of medications (crushing when not recommended)

The health impact for patients suffering from high blood pressure can be inconsistent blood pressure control, increased risk of stroke and heart attack, higher rates of hospitalization, and decreased quality of life.

While dysphagia can affect people of all ages, certain populations are at higher risk.